For the quarter ending 2026-03-31, RPRX made $630,576K in revenue. $294,690K in net income. Net profit margin of 46.73%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total income and other revenues | 630,576 | 621,990 | 609,291 | 578,665 |
| Provision for changes in expected cash flows from financial royalty assets | -197,485 | 23,105 | 12,135 | -203,938 |
| Provision for credit gaines on unfunded commitments | -3,700 | -4,269 | 766 | 92,535 |
| Research and development funding expense | 39,790 | 50,500 | 50,500 | 300,500 |
| General and administrative expenses (includes 122,292 and 703 of share-based compensation expense for the three months ended march 31, 2026 and 2025, respectively see note 4) | 159,490 | 164,273 | 118,734 | 179,769 |
| Financial royalty asset impairment | 69,443 | - | - | - |
| Total operating expense, net | 67,538 | 233,609 | 182,135 | 368,866 |
| Operating income | 563,038 | 388,381 | 427,156 | 209,799 |
| Equity in earnings of equity method investees | 21,758 | 4,005 | 15,948 | 2,693 |
| Interest expense | 93,722 | 94,171 | 79,564 | 68,668 |
| Losses on derivative financial instruments | - | -1,000 | 4,000 | -2,000 |
| Gaines on equity securities | -20,166 | 35,716 | 18,863 | -30,553 |
| Losses on available for sale debt securities | -6,680 | 24,080 | 52,480 | -27,420 |
| Interest income | 6,229 | 7,071 | 6,903 | 8,327 |
| Other non-operating expenses, net | -2,201 | -8,169 | -1,575 | -1,543 |
| Total other expense, net | -94,782 | -32,468 | 17,055 | -119,164 |
| Consolidated net income before tax | 468,256 | 355,913 | 444,211 | 90,635 |
| Income tax expense | 0 | 0 | 0 | 0 |
| Consolidated net income | 468,256 | 355,913 | 444,211 | 90,635 |
| Net income attributable to non-controlling interests | 173,566 | 141,708 | 155,994 | 60,459 |
| Net income attributable to royalty pharma plc | 294,690 | 214,205 | 288,217 | 30,176 |
| Basic EPS | 0.67 | 0.5 | 0.67 | 0.07 |
| Diluted EPS | 0.67 | 0.384 | 0.67 | 0.07 |
| Basic Average Shares | 436,790,000 | 428,323,000 | 431,887,000 | 423,514,000 |
| Diluted Average Shares | 556,837,000 | 557,809,000 | 559,611,000 | 562,298,000 |
Royalty Pharma plc (RPRX)
Royalty Pharma plc (RPRX)